How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,512 results for

High Pressure Injection Wound

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1501. Obesity in Adults

the absorption of dietary fat. It prevents absorption of around 30% of dietary fat. [ ] Effectiveness - orlistat significantly increases weight loss compared to placebo but its effectiveness is limited by its side-effects. [ ] Clinical trials suggest a moderate weight loss compared to placebo - about 2-5 kg over a year. There is also a small but significant reduction in total cholesterol, the ratio of total cholesterol to high-density lipids and systolic and diastolic blood pressure. Most patients gain (...) weight after stopping treatment but trials suggest it takes three years to gain weight lost in one year on the drug. Indications - individuals with a BMI of 28 kg/m 2 or more in the presence of significant comorbidities (eg, type 2 diabetes, high blood pressure, hyperlipidaemia) OR a BMI of 30 kg/m 2 or more with no associated comorbidities. [ ] These individuals should be on a mildly hypocaloric, low-fat diet. Prescription : Availability: this is now available over-the-counter (OTC) to individuals

2008 Mentor

1502. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension Full Text available with Trip Pro

and UDCA on liver fibrosis and portal hypertension induced by i.p. injection of carbon tetrachloride in rats. Our results demonstrated that although both treatments reduced liver collagen deposition, NCX-1000, but not UDCA, prevented ascite formation and reduced intrahepatic resistance in carbon tetrachloride-treated rats as measured by assessing portal perfusion pressure. In contrast to UDCA, NCX-1000 inhibited HSC contraction and exerted a relaxing effect similar to the NO donor S-nitroso-N (...) NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a leading cause of death in patients with liver cirrhosis, a scarring process of the liver that includes components of both increased fibrogenesis and wound contraction. A reduced production of nitric oxide (NO) resulting

2001 Proceedings of the National Academy of Sciences of the United States of America

1503. Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye

, patients return for follow-up visits once a month for 6 months. At these visits, several of the exams described above are repeated to evaluate treatment effects and check for adverse side effects. After 6 months, the implant is surgically removed. Post-surgical care for both implant and explant surgeries include examinations the day and week after surgery to examine the wound, a high dose of steroid immediately after surgery, oral antibiotics for 7 days, and eye drops for 1 week to prevent infection (...) be eligible for this study. Candidates will be screened with a medical history, physical examination, eye examinations, and eye photographs. The eye examination includes measurement of visual acuity and eye pressure, examination of the pupils and eye movements, and examination of the lens and back of the eye. In addition, patients will have the following tests: Visual field test: Patients look at a central spot on a white screen and tell the examiner whenever they see a small light appear at other places

2003 Clinical Trials

1504. Vertebroplasty for the Treatment of Fractures Due to Osteoporosis

options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have (...) Participants will receive percutaneous vertebroplasty Device: Percutaneous vertebroplasty Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture Placebo Comparator: Control Group Participants will receive sham vertebroplasty without PMMA Procedure: Sham vertebroplasty Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed. Outcome Measures Go to Primary Outcome Measures

2003 Clinical Trials

1505. Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

history of stroke, primary brain tumor or seizures not controlled by standard medical therapy. History of an active malignancy other than in situ carcinoma of the cervix, or non-melanomatous skin cancers in the last five years prior to Day 1 on study. Patients with non-healing wounds, bone fractures, or major surgery within the previous 28 days.. Uncontrolled hypertension (sustained systolic blood pressure greater than 160 mmHg or diastolic blood pressure of greater than 100 mmHg). Clinically (...) breast cancer. A small piece of tumor tissue and a small piece of skin from the affected breast are removed under local anesthesia for microscopic study. Dynamic MRI to examine changes in the blood vessels and breast cancer following bevacizumab treatment. This test involves injecting a contrast liquid into a vein before scanning. A standard MRI scan is done before the dynamic MRI. Blood tests are done to 1) study clot formation and breakdown, 2) measure levels of VEGF (a substance produced by breast

2001 Clinical Trials

1506. Single-dose antibiotic prophylaxis in maxillofacial surgery. (Abstract)

Single-dose antibiotic prophylaxis in maxillofacial surgery. The clinical efficacy of short-term antimicrobial prophylaxis with either one shot of ceftriaxone (1 g) or a course of 3 injections of a fixed combination of mezlocillin (2 g) and oxacillin (1 g) administered over 24 h was studied in a prospective randomized clinical study of 100 patients undergoing elective maxillofacial surgery. Tissue and plasma concentrations of the antibiotics were determined by high-pressure liquid (...) chromatography in 6 tumor surgery patients from each treatment group. Statistical analysis showed the treatment group to be comparable both demographically and with respect to the types of surgery performed and the durations of the procedures. Only 1 patient in each group developed a postoperative wound infection. It is concluded that 1 g ceftriaxone given 30 min preoperatively meets the pharmacokinetic requirements for perioperative antimicrobial prophylaxis in maxillofacial surgery.

1994 Chemotherapy Controlled trial quality: uncertain

1507. A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2007 Clinical Trials

1508. Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

Lacerations Device: cyanoacrylate with pressure sensitive mesh Device: cyanoacrylate Phase 2 Detailed Description: According to the literature, cyanoacrylate adhesives (topical skin adhesive) have performed as intended and have not produced results that would bring into question the safety or effectiveness of cyanoacrylate adhesive for closure of surgical incisions and traumatic wounds in humans. As such, this is a multicenter, prospective, randomized controlled study for the purpose of comparing two (...) : Arms and Interventions Go to Arm Intervention/treatment Experimental: Dermabond Protape DERMABOND PROTAPE (Prineo) Topical Skin Adhesive Device: cyanoacrylate with pressure sensitive mesh Topical Skin Adhesive Other Names: Dermabond Protape Prineo Active Comparator: Dermabond HVD DERMABOND HVD Topical Skin Adhesive Device: cyanoacrylate Topical Skin Adhesive Other Names: Dermabond - HVD Dermabond - Protape Outcome Measures Go to Primary Outcome Measures : The Incidence of Wound Closure Post

2007 Clinical Trials

1509. [Nuclear medicine studies of tissue concentration and hemodynamic effects of retrograde intravenous pressure infusions]. (Abstract)

intraarterial and 7 times higher than after intravenous injection of the same dose. The high count-rates which can be measured in the wound-secretion demonstrate the "rinsing effect" of the injected fluid. Hemodynamic investigations have been performed in a double blind study. 8 patients received buflomedil and 9 got placebo 3 times per week by retrograde intravenous pressure infusions. After 3 weeks there was an increase of the peak-flow on the lower leg (venous occlusion plethysmography), an increase (...) [Nuclear medicine studies of tissue concentration and hemodynamic effects of retrograde intravenous pressure infusions]. In 12 patients with trophic foot-lesions (diabetic feet) retrograde intravenous pressure infusions (150 ml) containing radioactive tracers (99m Tc, 99m Tc labelled human serum albumin) were carried out. With the veins emptied time-activity curves over the legs reflect tissue concentrations after release of the occlusion. Tissue-concentration is about 3 times higher than after

1993 Wiener medizinische Wochenschrift (1946) Controlled trial quality: uncertain

1510. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia Full Text available with Trip Pro

by transcutaneous oxygen tension (TcPo(2)) in patients with critical limb ischemia (CLI).Randomized patients with rest pain or ischemic ulcers and TcPo(2) <40 mm Hg and/or toe pressure <50 mm Hg received placebo or HGF-plasmid intramuscular injection as follows: 0.4 mg at days 0, 14, and 28 (low dose); 4.0 mg at days 0 and 28 (middle dose); or 4.0 mg at days 0, 14, and 28 (high dose). Patients were evaluated for safety, changes in TcPo(2) and ankle and toe pressure, amputation, and wound healing. Ninety-three (...) of 104 treated patients were evaluated for safety (mean age 70 years, 63% male, 53% diabetic, 64% with tissue loss, mean ankle-brachial index 0.41, and mean toe pressure 26 mm Hg). Adverse events occurred in 86% of the patients, most of which were related to CLI or comorbid conditions and were not different between groups. TcPo(2) (mean+/-SE) increased at 6 months in the high-dose group (24.0+/-4.2 mm Hg, 95% CI 15.5 to 32.4 mm Hg) compared with the placebo (9.4+/-4.2 mm Hg, 95% CI 0.9 to 17.8), low

2008 EvidenceUpdates Controlled trial quality: predicted high

1511. Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

are healing after injury. Consenting male and female cervical and high thoracic (T10 and above) SCI patients will be identified within the first 6-7 weeks after SCI and randomized to two external urethral sphincter injection groups. Each group will be injected within 8 weeks after SCI (Day 0) and 3 months later (Day 90). The injection paradigm will consist of: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90; Group 2-sham saline injections on both (...) Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2008 Clinical Trials

1512. The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers

wound healing or wound closure at a faster rate than conventional treatment. Condition or disease Intervention/treatment Phase Diabetic Wounds Venous Stasis Wounds Procedure: injection of lipoaspirate Other: control Not Applicable Detailed Description: Diabetic lower extremity wounds and venous stasis wounds are two of the most challenging, costly medical problems of our population. Moreover, the Veterans Affairs population has a very high percentage of diabetes and venous stasis wounds. Foot ulcers (...) The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>